Melanoma metabolism contributes to the cellular responses to MAPK/ERK pathway inhibitors
- 1 April 2018
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1862 (4) , 999-1005
Abstract
No abstract availableKeywords
Funding Information
- Ligue Contre le Cancer (7FI12469RPPL)
This publication has 58 references indexed in Scilit:
- Cancer heterogeneity is not compatible with one unique cancer cell metabolic mapOncogene, 2016
- AMPK Is Essential to Balance Glycolysis and Mitochondrial Metabolism to Control T-ALL Cell Stress and SurvivalCell Metabolism, 2016
- Enhanced OXPHOS, glutaminolysis and β-oxidation constitute the metastatic phenotype of melanoma cellsBiochemical Journal, 2016
- Reexamining How Cancer Cells Exploit the Body's Metabolic ResourcesCold Spring Harbor Symposia on Quantitative Biology, 2016
- A Mitochondrial Switch Promotes Tumor MetastasisCell Reports, 2014
- Metabolic Features of Melanoma: A Gold Mine of New Therapeutic Targets?Current Cancer Drug Targets, 2014
- Pathways and therapeutic targets in melanomaOncotarget, 2014
- Inactivation of the HIF-1α/PDK3 Signaling Axis Drives Melanoma toward Mitochondrial Oxidative Metabolism and Potentiates the Therapeutic Activity of Pro-OxidantsCancer Research, 2012
- Mutations of the BRAF gene in human cancerNature, 2002
- On the Origin of Cancer CellsScience, 1956